MCID: DST006
MIFTS: 43

Diastolic Heart Failure

Categories: Cardiovascular diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Diastolic Heart Failure

MalaCards integrated aliases for Diastolic Heart Failure:

Name: Diastolic Heart Failure 11 14 16
Heart Failure, Diastolic 43 71

Classifications:



External Ids:

Disease Ontology 11 DOID:9775
ICD9CM 34 428.3
MeSH 43 D054144
SNOMED-CT 68 418304008
UMLS 71 C1135196

Summaries for Diastolic Heart Failure

MalaCards based summary: Diastolic Heart Failure, also known as heart failure, diastolic, is related to hypertension, diastolic and amyloidosis. An important gene associated with Diastolic Heart Failure is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Cardiac conduction and Platelet homeostasis. The drugs Sodium citrate and Sildenafil have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and bone marrow, and related phenotypes are homeostasis/metabolism and muscle

Related Diseases for Diastolic Heart Failure

Diseases related to Diastolic Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 399)
# Related Disease Score Top Affiliating Genes
1 hypertension, diastolic 30.7 REN ACE
2 amyloidosis 30.5 TTR NPPB INS CRP
3 subclavian steal syndrome 30.4 CRP ACE
4 pericarditis 30.4 TNNT2 TNNI3 NPPB CRP ACE
5 infective endocarditis 30.3 NPPB CRP ACE
6 wild-type amyloidosis 30.3 TTR NPPB
7 central sleep apnea 30.2 REN NPPB CRP ACE
8 atrial fibrillation 30.2 TNNI3 NR3C2 NPPB CRP AGTR1 ACE
9 deficiency anemia 30.2 TTR REN INS CRP ACE
10 cardiomyopathy, familial hypertrophic, 1 30.2 TTN TNNT2 TNNI3 RBM20 MYH6 MYBPC3
11 coronary heart disease 1 30.2 INS CRP ACE
12 raynaud disease 30.1 PDE5A EDN1 CRP AGTR1
13 cardiac tamponade 30.1 TNNI3 REN NPPB CRP ACE
14 aortic valve insufficiency 30.1 TNNI3 REN NPPB CRP ACE
15 alcohol use disorder 30.1 INS CRP ACE
16 polycystic kidney disease 1 with or without polycystic liver disease 30.1 REN NOS3 ACE
17 atrial standstill 1 30.1 TTR NPPB MYBPC3 EDN1
18 diabetes mellitus, ketosis-prone 30.1 REN INS CRP ACE
19 eclampsia 30.0 REN NOS3 EDN1 ACE
20 acute myocarditis 30.0 TNNT2 TNNI3 REN NPPB CRP ACE
21 transient cerebral ischemia 29.9 REN NPPB INS CRP ACE
22 pulmonary hypertension 29.9 REN PRKG1 PDE5A NPPB NOS3 EDN1
23 pulmonary edema 29.9 TNNT2 TNNI3 REN NPPB NOS3 EDN1
24 amyloidosis, hereditary, transthyretin-related 29.9 TTR TNNT2 NPPB MYBPC3
25 cardiac arrest 29.9 TNNT2 TNNI3 NPPB CRP ACE
26 autosomal dominant polycystic kidney disease 29.8 REN NOS3 EDN1 CRP ACE
27 arteriosclerosis 29.8 TTR INS EDN1 CRP ACE
28 respiratory failure 29.7 TTR TTN TNNI3 REN NPPB INS
29 third-degree atrioventricular block 29.7 TTN TNNI3 REN NPPB MYH6 CRP
30 constrictive pericarditis 29.7 TTR TTN TNNT2 TNNI3 REN NPPB
31 peripartum cardiomyopathy 29.7 TTN RBM20 NR3C2 NPPB MYH6 MYBPC3
32 sleep apnea 29.6 REN NPPB NOS3 INS EDN1 CRP
33 angina pectoris 29.6 TNNI3 NPPB NOS3 INS EDN1 CRP
34 peripheral vascular disease 29.6 REN PDE5A NOS3 INS EDN1 CRP
35 myocarditis 29.6 TTN TNNT2 TNNI3 NPPB MYH6 EDN1
36 mitral valve insufficiency 29.6 TTN TNNT2 TNNI3 REN NR3C2 NPPB
37 vascular disease 29.5 TTR PDE5A NOS3 INS EDN1 CRP
38 congestive heart failure 29.5 TTN TNNT2 TNNI3 REN PDE5A NR3C2
39 intermediate coronary syndrome 29.5 TNNT2 TNNI3 REN NPPB INS EDN1
40 apnea, obstructive sleep 29.5 REN NR3C2 NPPB NOS3 INS EDN1
41 atherosclerosis susceptibility 29.5 NOS3 INS EDN1 CRP AGTR1 ACE
42 arteries, anomalies of 29.4 TNNI3 REN NOS3 INS EDN1 CRP
43 kidney disease 29.4 TTR REN NR3C2 NPPB NOS3 INS
44 systolic heart failure 29.4 TTN TNNT2 TNNI3 REN PDE5A NR3C2
45 tricuspid valve insufficiency 29.3 TNNT2 TNNI3 REN PDE5A NR3C2 NPPB
46 aortic valve disease 2 29.2 TTR TTN TNNT2 TNNI3 REN NPPB
47 left bundle branch hemiblock 29.2 TTN TNNT2 TNNI3 REN NR3C2 NPPB
48 stroke, ischemic 29.2 REN NR3C2 NPPB NOS3 INS CRP
49 renal hypertension 29.2 REN NR3C2 NOS3 INS EDN1 CRP
50 pre-eclampsia 29.2 REN PDE5A NOS3 INS EDN1 CRP

Graphical network of the top 20 diseases related to Diastolic Heart Failure:



Diseases related to Diastolic Heart Failure

Symptoms & Phenotypes for Diastolic Heart Failure

MGI Mouse Phenotypes related to Diastolic Heart Failure:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 ACE AGTR1 ATP2A2 CRP EDN1 INS
2 muscle MP:0005369 10.25 ATP2A2 EDN1 INS MYBPC3 MYH6 NOS3
3 cardiovascular system MP:0005385 10.23 ACE AGTR1 ATP2A2 CRP EDN1 INS
4 growth/size/body region MP:0005378 10.22 ACE AGTR1 ATP2A2 EDN1 INS LGALS3
5 renal/urinary system MP:0005367 10.17 ACE AGTR1 ATP2A2 EDN1 INS LGALS3
6 behavior/neurological MP:0005386 9.97 ACE AGTR1 ATP2A2 INS LGALS3 MYBPC3
7 immune system MP:0005387 9.73 ACE AGTR1 ATP2A2 CRP INS LGALS3
8 mortality/aging MP:0010768 9.5 ACE AGTR1 ATP2A2 EDN1 INS LGALS3

Drugs & Therapeutics for Diastolic Heart Failure

Drugs for Diastolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
2
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
3
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
4
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
5
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
6
Regadenoson Approved, Investigational Phase 4 313348-27-5 22451303 219024
7
Adenosine Approved, Investigational Phase 4 58-61-7 60961
8
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
9
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
10
Ertugliflozin Approved, Investigational Phase 4 1210344-57-2 75075340 44814423
11
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
12
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
13
Atenolol Approved Phase 4 29122-68-7 2249
14
Labetalol Approved Phase 4 36894-69-6 3869
15
Acebutolol Approved, Investigational Phase 4 37517-30-9 1978
16
Betaxolol Approved, Investigational Phase 4 659-18-7, 63659-18-7 2369
17
Penbutolol Approved, Investigational Phase 4 36507-48-9, 38363-40-5 37464
18
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
19
Bisoprolol Approved Phase 4 66722-44-9 2405
20
Nadolol Approved Phase 4 42200-33-9 39147
21
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
22
Pindolol Approved, Investigational Phase 4 13523-86-9 4828
23
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
24
Eplerenone Approved Phase 4 107724-20-9 443872
25
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
26
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
27
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
28 Phosphodiesterase Inhibitors Phase 4
29 Phosphodiesterase 5 Inhibitors Phase 4
30 Citrate Phase 4
31 Cardiotonic Agents Phase 4
32
Angiotensinogen Phase 4 16133225
33 Angiotensin Receptor Antagonists Phase 4
34 Angiotensin II Type 1 Receptor Blockers Phase 4
35 Giapreza Phase 4
36 Dopamine Agents Phase 4
37 Sodium Potassium Chloride Symporter Inhibitors Phase 4
38 Antioxidants Phase 4
39 Protective Agents Phase 4
40 Calcium, Dietary Phase 4
41 calcium channel blockers Phase 4
42 Sodium-Glucose Transporter 2 Inhibitors Phase 4
43 Sympathomimetics Phase 4
44 Adrenergic alpha-Antagonists Phase 4
45 Adrenergic alpha-1 Receptor Antagonists Phase 4
46 Adrenergic beta-1 Receptor Antagonists Phase 4
47 Adrenergic Antagonists Phase 4
48 Anti-Arrhythmia Agents Phase 4
49 Sympatholytics Phase 4
50 Neurotransmitter Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 142)
# Name Status NCT ID Phase Drugs
1 Aldosterone Antagonism in Diastolic Heart Failure Completed NCT00108251 Phase 4 Eplerenone;Placebo
2 A Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Determine the Effects of Valsartan on Exercise Time in Subjects With Symptomatic Diastolic Heart Failure Completed NCT00171106 Phase 4 valsartan
3 Novel Treatment for Diastolic Heart Failure in Women Completed NCT00206232 Phase 4 Spironolactone
4 Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart Completed NCT01944384 Phase 4 aldactone
5 Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF Completed NCT02589977 Phase 4 regadenoson
6 Randomized Evaluation of Heart Failure With Preserved Ejection Fraction (HFpEF) Patients With Acute Heart Failure and Dopamine (ROPA-DOP) Trial Completed NCT01901809 Phase 4 Furosemide;Dopamine
7 A Phase 4, Single-center, Randomized, Parallel Group Study to Assess Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus Completed NCT03753087 Phase 4 Empagliflozin
8 SIDAMI - Sildenafil and Diastolic Dysfunction After AMI Completed NCT01046838 Phase 4 Sildenafil;Placebo
9 A Phase 4, Randomized, Open Label, Multicenter Prospective Comparative Study To Evaluate The Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure Recruiting NCT04160000 Phase 4 Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation;Empiric heart failure drug therapy
10 The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure Recruiting NCT04071626 Phase 4 Ertugliflozin 5 mg;Placebo oral tablet
11 N-of-1 Trials for Deprescribing Beta-blockers in HFpEF Recruiting NCT04767061 Phase 4 Beta blockers
12 N-of-1 Trials for Deprescribing Beta-blockers in HFpEF Recruiting NCT04757584 Phase 4 Beta blockers
13 Echocardiographic Assessment of Pulmonary Transit Time Following Exercise Active, not recruiting NCT04336995 Phase 4
14 A Preliminary Study for the Intervention of an N-of-1 Protocol For Medication Optimization Not yet recruiting NCT05585125 Phase 4 Beta blocker
15 Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure Terminated NCT02053246 Phase 4 Nebivolol
16 The Use of Nesiritide in the Management of Acute Diastolic Heart Failure Terminated NCT00083772 Phase 4 Nesiritide
17 Determine the Effectiveness of Eplerenone in Reversing Diastolic Dysfunction, Improving Endothelial Function, and Suppressing Natriuretic Peptides and Collagen Turnover in Patients With Diastolic Heart Failure ( PREDICT Study) Terminated NCT00293150 Phase 4 Eplerenone
18 Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction Terminated NCT00799435 Phase 4 Exenatide
19 Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction: Phase III, Randomized, Double-blind, Placebo-controlled Trial [ULTIMATE-HFpEF Trial] Unknown status NCT01599117 Phase 3 Placebo;Udenafil (Zydena)
20 Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years) (OPTIMIZE-HFPEF) Unknown status NCT02425371 Phase 3
21 Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) Completed NCT00763867 Phase 3 Placebo;Sildenafil
22 Exercise Intolerance in Elderly Diastolic Heart Failure Completed NCT00123955 Phase 3 Spironolactone;Placebo
23 Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure Completed NCT01411735 Phase 3 Enalapril;placebo
24 Pulmonary Hypertension Secondary to Heart Failure With Preserved Systolic Function: a Target of Phosphodiesterase - 5 Inhibition in a 1- Year Duration Study Completed NCT01156636 Phase 2, Phase 3 Sildenafil;Placebo
25 Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension Completed NCT00820352 Phase 3 bosentan;placebo
26 Effects of Sildenafil on Pulmonary Arterial Pressure in Patients With Heart Failure With Preserved Ejection Fraction ( HFpEF) and Pulmonary Hypertension Completed NCT01726049 Phase 3 Sildenafil;Placebo
27 Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction Recruiting NCT05139472 Phase 3 Empagliflozin 10 MG
28 Sympathetic Renal Denervation in Heart Failure With Normal LV Ejection Fraction: Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction Terminated NCT01583881 Phase 2, Phase 3
29 Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction. A 35-week, Single-center, Prospective, Double-blind, Controlled, Randomized, 2x2 Crossover, Interventional Phase II Study, Investigating the Effect of Treatment With Dapagliflozin 10mg od on Left Ventricular Distensibility in Patients With Early HFpEF. Unknown status NCT04475042 Phase 2 Dapagliflozin;Placebo
30 A Pilot Study Of ALT-711 In Elderly Patients With Isolated Diastolic Heart Failure: The DIAMOND Study Completed NCT00043836 Phase 2 ALT-711
31 A Study of the Acute Hemodynamic and Myocardial Effects of Nesiritide in Diastolic Heart Failure. Completed NCT00309868 Phase 1, Phase 2 neseritide
32 A Phase 2 Randomised, Double-Blind, Placebo-Controlled Exploratory Efficacy Study Of Sitaxsentan Sodium To Improve Impaired Exercise Tolerance In Subjects With Diastolic Heart Failure Completed NCT00303498 Phase 2 Sitaxsentan sodium;Placebo
33 Randomised Double Blind Placebo Controlled Trial of Perhexiline in Heart Failure With Preserved Ejection Fraction Syndrome (HFpEF) Completed NCT00839228 Phase 2 Perhexiline;Placebo
34 Evaluation of Efficacy and Safety of Metoprolol XR in Patients Having Heart Failure With Normal Ejection Fraction: A Randomised, Double Blind,Placebo Controlled Trial Completed NCT03882710 Phase 2 Metoprolol XR
35 Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF Completed NCT02256345 Phase 2 KNO3;KCl
36 A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients With Heart Failure With Preserved Ejection Fraction Completed NCT01163734 Phase 2 Ranolazine
37 Reducing Symptom Burden in Patients With Heart Failure With Preserved Ejection Fraction Using Ubiquinol and/or D-ribose Completed NCT03133793 Phase 2 CoQ10;D-Ribose Oral Powder
38 Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function Completed NCT01182805 Phase 1, Phase 2
39 A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension Completed NCT01431313 Phase 2 Inhaled Nitrite
40 Prevention of Age-associated Cardiac and Vascular Dysfunction Through Nrf2 Signaling Using the Nutritional Supplement Sulforaphane Recruiting NCT05408559 Phase 1, Phase 2 Sulforaphane
41 Regress-HFPEF: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs Active, not recruiting NCT02941705 Phase 2
42 A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure Terminated NCT00662116 Phase 2 alagebrium;placebo
43 A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure Terminated NCT01913301 Phase 2 Alagebrium
44 Acute Hemodynamic Effects of Riociguat (BAY63-2521) in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure: A Randomized, Double-blind, Placebo-controlled, Single-dose Study in Three Ascending Dose Cohorts Terminated NCT01172756 Phase 2 Riociguat (BAY63-2521);Placebo
45 If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure Withdrawn NCT00757055 Phase 2 Ivabradine;Placebo
46 GRAPe Seed Extract and Ventriculovascular Investigation in Normal Ejection-Fraction Heart Failure Completed NCT01185067 Phase 1 grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
47 Phase 1 Open Label, Dose Escalation Trial of Intracoronary Infusion of NAN-101 in Subjects With NYHA Class III Heart Failure Recruiting NCT04179643 Phase 1
48 Diastolic Heart Failure Management by Nifedipine Unknown status NCT01157481 Conventional therapy plus nifedipine;Conventional therapy
49 Markers of Oxidative Stress Present in Blood in Patients With Diastolic Dysfunction Unknown status NCT00846404
50 Effect of Pedometer-Based Walking Intervention on Functional Capacity and Neurohumoral Modulation in Patients With Chronic Heart Failure With Preserved Ejection Fraction: a Multicenter Randomized Controlled Trial Unknown status NCT03041376

Search NIH Clinical Center for Diastolic Heart Failure

Cochrane evidence based reviews: heart failure, diastolic

Genetic Tests for Diastolic Heart Failure

Anatomical Context for Diastolic Heart Failure

Organs/tissues related to Diastolic Heart Failure:

MalaCards : Heart, Brain, Bone Marrow, Endothelial, Bone, Kidney, Cardiac Myocytes

Publications for Diastolic Heart Failure

Articles related to Diastolic Heart Failure:

(show top 50) (show all 1308)
# Title Authors PMID Year
1
Interdisciplinary Protocol for the Management of Vision-Threatening Papilledema. 62
35439211 2022
2
Managing Diastolic Dysfunction Perioperatively. 62
36473032 2022
3
High-normal diastolic blood pressure as a risk factor for left ventricular diastolic dysfunction in healthy postmenopausal women. 62
36202980 2022
4
Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here. 62
35604573 2022
5
A Pressing Matter: Compressive Postoperative Hematoma Causing Acute Diastolic Heart Failure. 62
36369117 2022
6
Peripartum Cardiomyopathy. 62
36458061 2022
7
Peak O2 -pulse predicts exercise training-induced changes in peak V̇O2 in heart failure with preserved ejection fraction. 62
35840541 2022
8
Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST-CHF study. 62
36184749 2022
9
Thirty-day readmission in patients with heart failure with preserved ejection fraction: Insights from the nationwide readmission database. 62
36187428 2022
10
Association between DLCO index and the severity of heart failure: a cross-sectional study. 62
36082926 2022
11
Imaging in Pulmonary Vascular Disease-Understanding Right Ventricle-Pulmonary Artery Coupling. 62
35950653 2022
12
Obstructive sleep apnea, chronic obstructive pulmonary disease and hypertensive microvascular disease: a cross-sectional observational cohort study. 62
35922660 2022
13
[Update on diastolic heart failure]. 62
35286435 2022
14
Diagnosis of heart failure in the elderly: current status and future perspectives for echocardiographic diagnostic systems. 62
35759116 2022
15
Flood syndrome: a rare case of spontaneous rupture of umbilical hernia in a cirrhotic patient. 62
35712608 2022
16
A Rapidly Accumulating Effusion in an Immunocompetent Woman. 62
35680319 2022
17
Furosemide-Induced Thrombotic Thrombocytopenic Purpura: A Report of a Rare Case. 62
35812544 2022
18
Trends in Hospital Admissions for Systolic and Diastolic Heart Failure in the United States Between 2004 and 2017. 62
35365288 2022
19
Left Atrial Circulatory Assistance in Simulated Diastolic Heart Failure Model: First in Vitro and in Vivo. 62
35027316 2022
20
Risk factors, resource use, and cost of postoperative low cardiac output syndrome. 62
32800368 2022
21
Machine-learning-based exploration to identify remodeling patterns associated with death or heart-transplant in pediatric-dilated cardiomyopathy. 62
35063339 2022
22
The Half-Century Mark: Explant of Ball and Cage Valve after 50 Years. 62
35221856 2022
23
Left atrial reservoir strain as a predictor of cardiac outcome in patients with heart failure: the HaFaC cohort study. 62
35287575 2022
24
Kaposiform lymphangiomatosis presenting with a Group A Streptococcus pericardial effusion. 62
35232734 2022
25
The Dysfunctional Scenario of the Major Components Responsible for Myocardial Calcium Balance in Heart Failure Induced by Aortic Stenosis. 62
35262582 2022
26
Surgical management of diastolic heart failure after septal myectomy for obstructive hypertrophic cardiomyopathy. 62
35169725 2022
27
How to build a successful hypertrophic cardiomyopathy team and ensure training the next generation of myectomy surgeons. 62
35167375 2022
28
Bariatric surgery decreases the number of future hospital admissions for diastolic heart failure in subjects with severe obesity: a retrospective analysis of the US National Inpatient Sample database. 62
34756668 2022
29
Pulmonary arterial hypertension in the elderly population. 62
34759211 2022
30
Evaluation of left atrial dysfunction by speckle tracking echocardiography in systolic and diastolic heart failure. 62
35086330 2022
31
Comment on: Bariatric surgery decreases the number of hospital admissions for diastolic heart failure in subjects with severe obesity. Retrospective analysis of the US National Inpatient Sample database. 62
34656453 2022
32
Gastroduodenal ischemia in a patient with severe SARS-CoV-2 infection. 62
34315220 2022
33
Material property alterations for phenotypes of heart failure with preserved ejection fraction: A numerical study of subject-specific porcine models. 62
36312535 2022
34
The Value of Echocardiography Combined with NT-pro BNP Level in Assessment and Prognosis of Diastolic Heart Failure. 62
35169397 2022
35
Diagnostic Tools for Cardiac Amyloidosis: A Pragmatic Comparison of Pathology, Imaging and Laboratories. 62
35007639 2022
36
Application of Combined Detection of Echocardiography and Serum NT-ProBNP in the Diagnosis of Diastolic Heart Failure and Its Effect on Left Ventricular Morphology and Diastolic Function. 62
35656473 2022
37
Pediatric Diastolic Heart Failure: Clinical Features Description of 421 Cases. 62
35586825 2022
38
Evaluating the adverse outcome of subtypes of heart failure with preserved ejection fraction defined by machine learning: A systematic review focused on defining high risk phenogroups. 62
35391918 2022
39
Myofilament Phosphorylation in Stem Cell Treated Diastolic Heart Failure. 62
34641704 2021
40
NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial. 62
34569641 2021
41
Pericardiectomy for Constrictive Pericarditis: Analysis of Outcomes. 62
33722460 2021
42
Influence of baseline parameters on one-year physical, mental, and health-related quality of life in patients with heart failure and preserved ejection fraction. 62
34480783 2021
43
Predictors of thirty-day readmission in nonagenarians presenting with acute heart failure with preserved ejection fraction: a nationwide analysis. 62
35136396 2021
44
An Unusual Case of Heart Failure: Sometimes When You Hear Hoof Beats You Should Think of Zebras. 62
35141062 2021
45
Immunoglobulin Light Chain Amyloidosis Presenting as Inferior Vena Cava Thrombosis. 62
34743583 2021
46
Constrictive pericarditis following heart transplantation: Reality or fiction? 62
34755387 2021
47
Comparing outcomes of diabetic ketoacidosis hospitalisations in patients with diastolic heart failure: A retrospective propensity matched analysis of the nationwide inpatient sample. 62
33440066 2021
48
Cardiac Amyloidosis: Presentations, Diagnostic Work-up and Collaborative Approach for Comprehensive Clinical Management. 62
34175153 2021
49
Factors predicting futility of liver transplant in elderly recipients: A single-center experience. 62
34722171 2021
50
Deep-Learning Models for the Echocardiographic Assessment of Diastolic Dysfunction. 62
34023263 2021

Variations for Diastolic Heart Failure

Expression for Diastolic Heart Failure

Search GEO for disease gene expression data for Diastolic Heart Failure.

Pathways for Diastolic Heart Failure

Pathways related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.43 TTN TNNT2 TNNI3 PDE5A MYH6 MYBPC3
2
Show member pathways
11.97 PRKG1 PDE5A NOS3 ATP2A2
3 11.61 TNNT2 TNNI3 INS
4 11.28 TNNT2 TNNI3 MYH6 INS
5
Show member pathways
11.22 TTN TNNT2 TNNI3 MYH6 MYBPC3
6
Show member pathways
11.16 REN PRKG1 NR3C2 NOS3 AGTR1 ACE
7
Show member pathways
11.12 PRKG1 PDE5A NOS3
8 10.99 NOS3 EDN1 ATP2A2
9 10.55 PDE5A NOS3

GO Terms for Diastolic Heart Failure

Cellular components related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myofibril GO:0030016 9.56 TNNT2 TNNI3 MYH6
2 sarcomere GO:0030017 9.56 TNNT2 TNNI3 MYH6 MYBPC3
3 cardiac Troponin complex GO:1990584 9.46 TNNT2 TNNI3
4 cardiac myofibril GO:0097512 9.1 TNNT2 TNNI3 MYBPC3

Biological processes related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 10.15 REN NOS3 EDN1 ACE
2 muscle contraction GO:0006936 10.03 TTN TNNT2 TNNI3 MYH6
3 vasodilation GO:0042311 9.97 INS NOS3 NPPB
4 sarcomere organization GO:0045214 9.95 MYH6 TNNT2 TTN
5 regulation of vasoconstriction GO:0019229 9.88 ACE AGTR1 EDN1
6 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.86 TNNI3 ATP2A2
7 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.86 TNNT2 TNNI3 MYH6 MYBPC3
8 vasoconstriction GO:0042310 9.85 EDN1 CRP ACE
9 cardiac muscle contraction GO:0060048 9.85 MYBPC3 MYH6 TNNI3 TNNT2 TTN
10 body fluid secretion GO:0007589 9.84 NPPB EDN1
11 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.83 NOS3 EDN1
12 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.81 AGTR1 ACE
13 renin-angiotensin regulation of aldosterone production GO:0002018 9.76 REN AGTR1
14 striated muscle contraction GO:0006941 9.72 TTN TNNI3 MYH6
15 regulation of blood pressure GO:0008217 9.7 REN NPPB NOS3 MYH6 EDN1 ACE
16 blood vessel diameter maintenance GO:0097746 9.28 NPPB NOS3 EDN1 AGTR1 ACE

Molecular functions related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.76 TTR NPPB INS EDN1
2 troponin C binding GO:0030172 9.26 TNNT2 TNNI3
3 bradykinin receptor binding GO:0031711 8.92 AGTR1 ACE

Sources for Diastolic Heart Failure

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....